Diagnosed arthritis afflicts 22% of the U.S. population and is projected to affect the lives of as many as 50% by 2030. Firstborn Baby Boomers recently reached 60 and the rest of that generation will continue to do so over the next 15 years, creating the largest senior citizen demographic in history, as well as one of the biggest disease indication growth markets.
The BioWorld Arthritis Report 2009: Drug and Med-Tech Innovation and Economics report delivers comprehensive data and strong analysis on the arthritis phenomenon which is poised to become a global burden on the healthcare system, payers and the population. BioWorld also details the promising prospects for investors in the field and provides a practical assessment of the R&D landscape for the scientific community.
Order the BioWorld Arthritis Report 2009: Drug and Med-Tech Innovation and Economics risk-free for 30 days for only $599 (Plus $17.95 S&H). Or call us at 1-800-688-2421 or 1-404-262-5476 and mention priority code S08443.